Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets – AI‑Driven Multi‑Omics Analysis

Fineline Cube Feb 25, 2026
Company Deals

YolTech Partners with XtalPi to Build AI‑Driven mRNA and CAR‑T Screening Platform – Closed‑Loop Dry‑Wet Lab Integration

Fineline Cube Feb 24, 2026
Company Deals

Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal – Expands Global RNAi Partnership

Fineline Cube Feb 24, 2026
Company Deals

Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal – Expands Global Footprint for CTLA‑4 Asset

Fineline Cube Feb 24, 2026
Company Deals

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

Fineline Cube Feb 24, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion – MCV4 Now Covers Children Up to 6 Years

Fineline Cube Feb 25, 2026
Company Drug

J&J’s RYBREVANT SC Dosing Approved by EC – Expands Subcutaneous Options Across All NSCLC Indications

Fineline Cube Feb 24, 2026
Company Drug

Doma Biopharmaceutical Receives FDA Clearance for Phase I Trial of EGFR-MET Targeting ADC, DM005

Fineline Cube Aug 30, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a Chinese pharmaceutical firm, has received approval from the U.S....

Company Drug

Jiyuan Biotechnology’s Stem Cell Therapy for Type 2 Diabetes Gains NMPA Tacit Approval for Clinical Trials

Fineline Cube Aug 30, 2024

BEIJING—Jiyuan Biotechnology, a leading Chinese biopharmaceutical company, has secured tacit clinical trial approval from the...

Company Deals

AstraZeneca Boosts Investment in Qingdao Aerosol Production Hub to $750 Million

Fineline Cube Aug 30, 2024

QINGDAO—AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced a further investment in its...

Company Medical Device

NMPA Suspends Jeisys Medical Inc.’s Nd:YAG Laser Equipment Over Quality Concerns

Fineline Cube Aug 30, 2024

BEIJING—The National Medical Products Administration (NMPA) of China has issued a notification to immediately suspend...

Company Drug

CNGB Virogin’s VG161 On Track for Breakthrough Designation in China for Advanced Liver Cancer

Fineline Cube Aug 30, 2024

BEIJING—CNGB Virogin, a joint venture between Virogin Biotech and China National Biotec Group, is poised...

Policy / Regulatory

China’s Healthcare Statistics Show Improvements in Life Expectancy and Access to Medical Services

Fineline Cube Aug 30, 2024

BEIJING—The National Health Commission (NHC) of China has published the “China’s Healthcare Statistical Communique 2023,”...

Company

Mindray Bio-Medical Electronics Reports 11.12% YOY Revenue Growth in 2024H1

Fineline Cube Aug 30, 2024

SHENZHEN—Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for the first...

Company

Hua Medicine’s 2024H1 Revenues Surge on HuaTangNing Sales; Path to Profitability in Sight

Fineline Cube Aug 30, 2024

HONG KONG—Hua Medicine (HKG: 2552), a China-based pharmaceutical company, has announced its financial results for...

R&D

American Government Funds Bolster Chinese Inventors’ Patents, According to USPTO Data

Fineline Cube Aug 30, 2024

WASHINGTON—A Reuters investigation into the United States Patent and Trademark Office (USPTO) data has uncovered...

Company

GeneQuantum Appoints Dr. Lingyu Zhu as Chief Business Strategy and Development Officer

Fineline Cube Aug 30, 2024

SUZHOU—GeneQuantum, a leading player in the biotech industry known for its cutting-edge enzymatic site-specific conjugation...

Policy / Regulatory

Jiangxi Healthcare Security Administration Launches Initiative to Widen Drug Availability

Fineline Cube Aug 29, 2024

JIANGXI—In a strategic move to enhance drug accessibility, the Healthcare Security Administration (HSA) bureau of...

Company Legal / IP

China’s Supreme Court Deals Blow to Sanofi’s Aubagio, Confirms Patent Cancellation

Fineline Cube Aug 29, 2024

BEIJING—In a recent development for the pharmaceutical industry, Sanofi’s multiple sclerosis therapy Aubagio (teriflunomide) has...

Company Deals

Pfizer Partners with Quotient Therapeutics for Somatic Mutations Research in Cardiovascular and Renal Diseases

Fineline Cube Aug 29, 2024

NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE),...

Company Deals

Sackler-Owned Mundipharma Fails to Secure $1 Billion Valuation for China Unit

Fineline Cube Aug 29, 2024

LONDON—Mundipharma International Ltd., the UK-based pharmaceutical firm with ties to the Sackler family of the...

Company Drug

Sinopharm and Ruidio Pharmaceutical Advance in Priority Review for Innovative Drugs and Vaccines

Fineline Cube Aug 29, 2024

BEIJING—The Center for Drug Evaluation (CDE) has indicated that two Chinese companies, Foshan Ruidio Pharmaceutical...

Company Drug

Jiangsu Simcere and AnDiConBio’s Anti-Influenza Drug ADC189 Doses First Patient in Phase III Study

Fineline Cube Aug 29, 2024

JIANGSU—In a significant development for the pharmaceutical industry, Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096),...

Company Drug

Sino Biopharmaceutical’s Anlotinib-Penpulimab Combo Meets Milestone in Phase III HCC Study

Fineline Cube Aug 29, 2024

HONG KONG—Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced...

Company Deals

Leaderna Therapeutics Secures RMB 100 Million in Funding to Accelerate Nucleic Acid Drug Development

Fineline Cube Aug 29, 2024

CHENGDU—Leaderna Therapeutics Ltd, a pioneering nucleic acid drug developer, has reportedly secured nearly RMB 100...

Company Medical Device

Advancing Peripheral Artery Disease Care: Boston Scientific’s JETSTREAM Receives Marketing Nod in China

Fineline Cube Aug 29, 2024

NEW YORK—Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical solutions, has secured a...

Policy / Regulatory

China’s New Medical Device Regulations: A Comprehensive Framework for Industry Growth and Safety

Fineline Cube Aug 29, 2024

BEIJING—China’s National Medical Products Administration (NMPA) has unveiled a draft proposal for the “Medical Device...

Posts pagination

1 … 265 266 267 … 626

Recent updates

  • CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion – MCV4 Now Covers Children Up to 6 Years
  • Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets – AI‑Driven Multi‑Omics Analysis
  • YolTech Partners with XtalPi to Build AI‑Driven mRNA and CAR‑T Screening Platform – Closed‑Loop Dry‑Wet Lab Integration
  • J&J Invests $1B+ in Pennsylvania Cell Therapy Facility – Expands Manufacturing for Cancer and Neurology Pipeline
  • Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal – Expands Global RNAi Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion – MCV4 Now Covers Children Up to 6 Years

Company Deals Digital

Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets – AI‑Driven Multi‑Omics Analysis

Company Deals

YolTech Partners with XtalPi to Build AI‑Driven mRNA and CAR‑T Screening Platform – Closed‑Loop Dry‑Wet Lab Integration

Company

J&J Invests $1B+ in Pennsylvania Cell Therapy Facility – Expands Manufacturing for Cancer and Neurology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.